6 results about "Nucleoplasm" patented technology

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

The invention discloses application of carfilzomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of nipah virus M protein, the carfilzomib is used for inhibiting a host proteasome path, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and the effect is good. At present, most of research and development of virus medicines and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of medicines and vaccines in the future, and a new application is also provided for Carfilzomib.

This disclosure provides methods and compositions to increase the efficiency of targeted coding RNA pseudouridylation by H / ACA snoRNA, by localizing the H / ACA snoRNA more to the nucleoplasm where pre-mRNAs are transcribed and processed into mature mRNAs versus the nucleolus, where H / ACA snoRNAs natively modify ribosomal RNAs.

The invention belongs to the technical field of biological medicine, and particularly relates to application of exosome miRNA as a gastric cancer diagnosis marker and a treatment target. The regulation and control effects of circulating exosome miRNA in early gastric cancer diagnosis and malignant progression are systematically analyzed, and it is found that miR-412-5p is remarkably low in expression in early gastric cancer. The scheme of the invention further confirms that the nucleoplasm transporter gene XPO1 is a direct target gene of miR-412-5p, and activation of a PI3K-AKT pathway can be driven by expression imbalance of the nucleoplasm transporter gene XPO1.

The application discloses a solution for separating fat cell nucleus and cytoplasm, and the solution comprises solution 1 and solution 2; wherein the solution 1 comprises 8-12 mM hydrochloride buffer, 0.03-0.15% Tween-20, 8-12 mM sodium chloride, 2-4 mM magnesium chloride, 0.8-2% bovine serum albumin and 0.4-0.6% ethyl phenyl polyethylene glycol; the solution 2 comprises 8-12 mM hydrochloride buffer, 8-25 mM sodium chloride, 1-15 mM magnesium chloride and 0.8-2.5% bovine serum albumin; the percentage is volume percentage. The application can realize the research on all cell types of fat tissues, greatly reduces the required amount of fat tissues and improves the possibility of carrying out single cell research. The application can be used for both transcriptome research and epigenetic research.

The invention discloses application of ixazomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of the nipah virus M protein, the host proteasome pathway is inhibited through the ixazomib, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and a good effect is achieved. The ixazomib is used as a nipah virus inhibitor, belongs to a new application of an old medicine, and provides a new application for the ixazomib. And the safety of the ixazomib has no problem, so that the ixazomib can be applied clinically. In addition, at present, most of research and development of virus drugs and vaccine research are designed or modified aiming at viruses, and a new thought is provided for research and development of drugs and vaccines in the future.